TradeUP (NASDAQ:UPTD) announced in an 8-K this morning that its shareholders approved its combination with Estrella Biopharma at a special meeting yesterday, July 31.
650,580 shares were redeemed in connection with the vote, leaving the SPAC with just 98,074 public shares remaining from its original IPO. Should these results stand, TradeUp will have finished its process with 94.8% of shares redeemed.
In addition to its roughly $1 million in remaining trust capital, the SPAC also secured a $6.8 million PIPE last week. This effectively allowed Estrella lender Eureka Therapeutics to convert about $6.8 million in debts into equity in the form of 680,000 units, each containing one common share and one preferred share.
But, this is still short of the deal’s minimum cash condition, which requires TradeUp to maintain $20 million in cash available unless waived. The SPAC secured a one-year extension to its transaction deadline last month, however, so it has time to make additional moves to shore up this cash situation.
Should the deal go to close as is, these PIPE shares are to be locked up for one year, so they would not ease the low-float scenario that would face Estrella at close. Perhaps in anticipation of this, TradeUp stock spiked up to about +77% in pre-market trading at one point this morning.
What is likely to have an impact is the common stock purchase agreement TradeUp signed with White Lion Capital in April. Under this agreement, White Lion is to purchase up to $50 million in shares in the combined company after close. The maximum investment for agreement would appear to be unavailable even if White Lion may purchase shares recently tendered for redemption.
But, White Lion will nonetheless be issued 250,000 shares shortly after close in return for having made its commitments, which would more than triple Estrella’s liquid public share count.
TradeUp initially announced its $398 million combination with Estrella Biopharma in October 2022. Emeryville, California-based Estrella is developing three potential cancer therapies aimed at improving the effectiveness of T-cell treatments.
At the SPAC of Dawn Futures continue to be green following a “hold steady” message out of the Fed and heading into jobless claims numbers and other indicators. US President Donald Trump has weighed in that he would like to see a rate cut sooner rather than later and differed with the body’s predictions on...
At the SPAC of Dawn Futures have tipped slightly green in anticipation of the Fed’s rate cut decision and follow several trading sessions in a row that ended positively in European markets. SPAC filings have meanwhile been notably light this week overall, as the uncertainty may have caused some pauses in activity as teams wait...
Renatus Tactical Acquisition Corp I has filed for a $175 million SPAC IPO, aiming to target high-potential U.S.-based businesses in cryptocurrency and blockchain, data security, and dual-use technologies. The blank-check company intends to list on the Nasdaq, nevertheless, it has not disclosed its symbols yet. The offering consists of 17,500,000 units priced at $10 each,...
Cohen Circle I (NASDAQ:CCIRU) has entered into a definitive agreement to combine with telecom and digital services company Kyivstar at a pro forma equity value of $2.2 billion, or 3.6x its 2024E adjusted EBITDA. Kyivstar is the market-leading mobile operator and broadband provider in Ukraine with 2 million more users on its digital TV platform...
At the SPAC of Dawn March gets its first SPAC IPO on the board later today as Quartzsea (NASDAQ:QSEAU) priced its slightly upsized $72 million offering after hours yesterday. Cohen Circle I (NASDAQ:CCIRU) also announced just the second deal of the month as well, and it is one that could hardly be more topical. The...